August 10, 2009 – The adoption of electronic medical records (EMRs) is ramping up in the United States due to President Obama's stimulus plan, designed to promote widespread EMR adoption by 2015, according to Millennium Research Group (MRG).

August 10, 2009 – SyntheMed Inc. said this week its antiadhesion product, the REPEL-CV Bioresorbable Adhesion Barrier, received the endorsement of Kids With Heart National Association for Children's Heart Disorders Inc.

August 7, 2009 – An innovative program that cut cardiac deaths by 73 percent by linking coronary artery disease patients and teams of pharmacists, nurses, primary care doctors, and cardiologists with an electronic health record (EHR) also kept the patients healthy two years after they left the program by keeping them in touch with their caregivers electronically, according to a randomized study

August 6, 2009 – Ziosoft Inc., an advanced visualization and analysis software for medical imaging, and Healthcare Software Systems Ltd. (HSS), a United Kingdom supplier of radiology information systems, have signed an agreement for HSS to distribute Ziosoft’s 3D thin-client software solutions in the U.K.

August 6, 2009 – Palatin Technologies Inc. said this week it received a notice of allowance from the U.S. Patent and Trademark Office covering a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, which is Palatin's lead heart failure drug candidate.

August 5, 2009 – The Society of Cardiovascular Computed Tomography (SCCT) named Chirapa Puntawangkoon, M.D., and Thananya Boonyasirinant, M.D., the winners of the third annual Young Investigator Award. Both winners were honored at SCCT’s 2009 Annual Scientific Meeting in Orlando, Fla.

August 5, 2009 – Stereotaxis Inc. said today clinicians performed more than 2,500 procedures with the magnetic irrigated catheter since its commercial release, and the major adverse cardiac event (MACE) rate for magnetic procedures remains at 0.1 percent.

August 4, 2009 – Watson Pharmaceuticals Inc. said this week it received FDA approval on its abbreviated new drug applications (ANDAs) for metoprolol succinate extended-release tablets USP in the 25 mg and 50 mg strengths, which are the generic equivalent to AstraZeneca's Toprol XL tablets.